Celldex Therapeutics, Inc. - Common Stock (CLDX)
CUSIP: 15117B202
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 67,629,115
- Total 13F shares
- 46,338,765
- Share change
- +2,820,297
- Total reported value
- $1,790,195,856
- Put/Call ratio
- 44%
- Price per share
- $38.64
- Number of holders
- 170
- Value change
- +$97,400,922
- Number of buys
- 87
- Number of sells
- 69
Quarterly Holders Quick Answers
What is CUSIP 15117B202?
CUSIP 15117B202 identifies CLDX - Celldex Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 15117B202:
Top shareholders of CLDX - Celldex Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
8.3%
|
5,615,333
|
$303,172,000 | — | 30 Sep 2021 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
5.8%
|
3,908,947
|
$211,044,000 | — | 30 Sep 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
4.6%
|
3,133,770
|
$169,191,000 | — | 30 Sep 2021 | |
| Redmile Group, LLC |
13F
|
Company |
4.5%
|
3,043,298
|
$164,308,000 | — | 30 Sep 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
2,276,199
|
$122,892,000 | — | 30 Sep 2021 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.2%
|
2,180,352
|
$117,717,000 | — | 30 Sep 2021 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
1,857,118
|
$100,266,000 | — | 30 Sep 2021 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
2.4%
|
1,600,000
|
$86,384,000 | — | 30 Sep 2021 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
1,128,000
|
$60,901,000 | — | 30 Sep 2021 | |
| VR Adviser, LLC |
13F
|
Company |
1.6%
|
1,098,174
|
$59,290,000 | — | 30 Sep 2021 | |
| Opaleye Management Inc. |
13F
|
Company |
1.5%
|
985,000
|
$53,045,000 | — | 30 Sep 2021 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.4%
|
950,000
|
$51,291,000 | — | 30 Sep 2021 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.3%
|
878,409
|
$47,425,000 | — | 30 Sep 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
792,507
|
$42,787,000 | — | 30 Sep 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.2%
|
783,061
|
$42,277,000 | — | 30 Sep 2021 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
1.1%
|
762,296
|
$41,156,000 | — | 30 Sep 2021 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.1%
|
761,398
|
$41,108,000 | — | 30 Sep 2021 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.1%
|
722,843
|
$39,026,000 | — | 30 Sep 2021 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
0.96%
|
649,278
|
$35,055,000 | — | 30 Sep 2021 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.81%
|
551,065
|
$29,752,000 | — | 30 Sep 2021 | |
| Invesco Ltd. |
13F
|
Company |
0.79%
|
533,985
|
$28,830,000 | — | 30 Sep 2021 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.78%
|
525,867
|
$28,392,000 | — | 30 Sep 2021 | |
| Vivo Capital, LLC |
13F
|
Company |
0.72%
|
484,453
|
$26,156,000 | — | 30 Sep 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.68%
|
459,113
|
$24,788,000 | — | 30 Sep 2021 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.61%
|
414,300
|
$22,368,000 | — | 30 Sep 2021 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.58%
|
393,613
|
$21,251,000 | — | 30 Sep 2021 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.53%
|
358,634
|
$19,362,000 | — | 30 Sep 2021 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.5%
|
337,500
|
$18,222,000 | — | 30 Sep 2021 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.48%
|
322,456
|
$17,410,000 | — | 30 Sep 2021 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.45%
|
307,679
|
$16,612,000 | — | 30 Sep 2021 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.4%
|
270,431
|
$14,600,000 | — | 30 Sep 2021 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.38%
|
255,000
|
$13,767,000 | — | 30 Sep 2021 | |
| Commodore Capital LP |
13F
|
Company |
0.37%
|
248,207
|
$13,401,000 | — | 30 Sep 2021 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.31%
|
211,453
|
$11,417,000 | — | 30 Sep 2021 | |
| Altium Capital Management LLC |
13F
|
Company |
0.27%
|
185,000
|
$9,988,000 | — | 30 Sep 2021 | |
| S.c.a. Candriam |
13F
|
Individual |
0.27%
|
180,222
|
$9,730,000 | — | 30 Sep 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.26%
|
177,529
|
$9,584,000 | — | 30 Sep 2021 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
172,746
|
$9,327,000 | — | 30 Sep 2021 | |
| AXA S.A. |
13F
|
Company |
0.24%
|
162,983
|
$8,800,000 | — | 30 Sep 2021 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
161,276
|
$8,707,000 | — | 30 Sep 2021 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.23%
|
153,960
|
$8,312,000 | — | 30 Sep 2021 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.22%
|
147,488
|
$8,022,000 | — | 30 Sep 2021 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.2%
|
137,032
|
$7,398,000 | — | 30 Sep 2021 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.19%
|
130,330
|
$7,037,000 | — | 30 Sep 2021 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.17%
|
113,924
|
$6,151,000 | — | 30 Sep 2021 | |
| CITIGROUP INC |
13F
|
Company |
0.16%
|
109,309
|
$5,902,000 | — | 30 Sep 2021 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.15%
|
102,146
|
$5,515,000 | — | 30 Sep 2021 | |
| Global IMC LLC |
13F
|
Company |
0.14%
|
96,528
|
$5,212,000 | — | 30 Sep 2021 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.14%
|
93,428
|
$5,044,000 | — | 30 Sep 2021 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.13%
|
86,399
|
$4,665,000 | — | 30 Sep 2021 |
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock (CLDX) as of Q4 2021
As of 31 Dec 2021,
Celldex Therapeutics, Inc. - Common Stock (CLDX) was held by
170 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,338,765 shares.
The largest 10 holders included
FMR LLC, RTW INVESTMENTS, LP, BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, Redmile Group, LLC, RA CAPITAL MANAGEMENT, L.P., EVENTIDE ASSET MANAGEMENT, LLC, and CITADEL ADVISORS LLC.
This page lists
171
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q3 2021 Across Filers
Q3 2021 holders
156
Q4 2021 holders
170
Holder diff
14
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.